

ASX/AIM Announcement

2 July 2025

Wellnex Life Limited (ASX/AIM:WNL)

Company Update

Divestment of The Iron Company

Wellnex Life Limited ("**Wellnex**" or the "**Company**") (ASX:WNL AIM:WNL), an innovative consumer healthcare business with a track record for developing, licensing, and marketing products and brands to customers in the growing healthcare market segment, is pleased to provide the following update.

After the successful listing on London's AIM market in March this year, the Board commenced an internal review of its operations to identify key brand assets to focus on, and invest in, over the medium to long term.

As part of this ongoing review, the Company has divested the assets of The Iron Company brand to CW Retail Holdings Pty Ltd (part of the Chemist Warehouse group), effective 30th June 2025 for no cash consideration, in lieu of trade activity that supports our Pain Away, Wakey Wakey and Nighty Night brands within the Chemist Warehouse group.

Joint CEO Zack Bozinovski commented "The Iron Company brand contributed less than 0.5% to Wellnex's gross margins and with our renewed strategy to focus on our key major brands such as Pain Away, Wakey Wakey and Nighty Night, the Company has taken the opportunity to divest the brand."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNL).

For further information, please contact:

Wellnex Life Limited (ASX:WNL)
George Karafotias or Zack Bozinovski
Joint Chief Executive Officers
P: +61 3 8399 9419
E: george.k@Wellnexlife.com.au

Reach Markets
T: 1300 805 9419
E: IR@reachmarkets.com.au

UK Investors

Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson / Robert Collins

Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)
Sebastian Wykeham

swykeham@oranacorp.com

S.P. Angel Corporate Finance LLP (Joint Broker)
David Hignell / Vadim Alexandre

Tel: +44 (0)20 3470 0470

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

